Related Experiment Video

Updated: Jun 16, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinases as targets in the treatment of solid tumors

Georgios Giamas1, Yik L Man, Heidrun Hirner

  • 1Department of Cancer and Surgery, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 ONN, UK. georgios.giamas@imperial.ac.uk

Cellular Signalling
|January 26, 2010
PubMed

Insights

Protein kinases regulate cell functions and are crucial in cancer development. Targeting these kinases offers promising cancer therapies, potentially improving upon conventional treatments.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oncology

Background:

  • Protein kinases are a large eukaryotic gene family regulating vital cellular processes.
  • Deregulation of protein kinases is frequently linked to cancer development.
  • Altered kinase expression, activity, and posttranslational modifications are implicated in solid tumors.

Purpose of the Study:

  • To review protein kinases involved in cancer signaling pathways.
  • To highlight the role of protein kinases in solid tumor development.
  • To discuss the therapeutic potential of targeting protein kinases in cancer.

Main Methods:

  • Literature review of scientific articles and clinical trials.
  • Focus on protein kinases and their signaling pathways in solid tumors.
  • Analysis of kinase alterations and their contribution to cancer.

Main Results:

  • Protein kinases are critical regulators of cell proliferation, survival, and death.
  • Aberrant kinase activity is a hallmark of many solid tumors.
  • Protein kinase inhibitors show promise in preclinical and clinical cancer trials.

Conclusions:

  • Targeting protein kinases is a key strategy in modern cancer drug development.
  • Protein kinase inhibitors offer a more targeted approach compared to conventional chemotherapy.
  • Combination therapies involving kinase inhibitors may lead to improved treatment outcomes.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...